Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.
- 06 Oct 2019 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 29 Apr 2019 Planned End Date changed from 2 Jul 2019 to 23 Jul 2019.